← Back to All US Stocks

CLNN Stock Analysis - Clene Inc. AI Rating

CLNN Nasdaq Pharmaceutical Preparations DE CIK: 0001822791
Recently Updated • Analysis: Mar 22, 2026 • SEC Data: 2025-12-31
AI Rating
STRONG SELL
95% Confidence

📊 CLNN Key Takeaways

Revenue: $200.0K
Net Margin: -13,086.5%
Free Cash Flow: $-18.6M
Current Ratio: 0.83x
Debt/Equity: N/A
EPS: $-0.46
AI Rating: STRONG SELL with 95% confidence

Investment Thesis

Clene Inc. exhibits severe financial distress with negative stockholders' equity of -$17.6M, massive operating losses, and critically weak liquidity. The company is burning cash at an unsustainable rate (-$18.6M FCF) with minimal revenue generation ($200K), indicating the business model is not viable in its current state and poses significant financial risk.

CLNN Strengths

  • + Maintains modest cash position of $5.2M providing short-term runway
  • + Revenue generation demonstrates some commercial traction despite minimal scale
  • + High insider activity (25 Form 4 filings) may indicate management confidence or restructuring efforts

CLNN Risks

  • ! Negative stockholders' equity of -$17.6M indicates technical insolvency and shareholder value destruction
  • ! Operating cash burn of -$18.5M annually with only $5.2M cash on hand creates critical liquidity crisis
  • ! Revenue collapsed 41.5% YoY to just $200K while operating losses remain severe at -$23.1M
  • ! Liabilities ($35.7M) exceed assets ($18.1M) by 97%, indicating structural financial failure
  • ! Current ratio of 0.83x shows inability to cover short-term obligations with current assets
  • ! Long-term debt of $17.8M is unsustainable given negative cash generation and minimal revenue

Key Metrics to Watch

CLNN Financial Metrics

Revenue
$200.0K
Net Income
$-26.2M
EPS (Diluted)
$-0.46
Free Cash Flow
$-18.6M
Total Assets
$18.1M
Cash Position
$5.2M

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

CLNN Profitability Ratios

Gross Margin N/A
Operating Margin -11,541.5%
Net Margin -13,086.5%
ROE N/A
ROA -144.4%
FCF Margin -9,292.5%

CLNN vs Healthcare Sector

How Clene Inc. compares to Healthcare sector averages

Net Margin
CLNN -13,086.5%
vs
Sector Avg 12.0%
CLNN Sector
ROE
CLNN 0.0%
vs
Sector Avg 15.0%
CLNN Sector
Current Ratio
CLNN 0.8x
vs
Sector Avg 2.0x
CLNN Sector
Debt/Equity
CLNN 0.0x
vs
Sector Avg 0.6x
CLNN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CLNN Balance Sheet & Liquidity

Current Ratio
0.83x
Quick Ratio
0.83x
Debt/Equity
N/A
Debt/Assets
197.0%
Interest Coverage
-8.61x
Long-term Debt
$17.8M

CLNN 5-Year Financial Trend

CLNN 5-year financial data: Year 2022: Revenue $723.0K, Net Income -$9.7M, EPS $-0.16.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Clene Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.67 indicates the company is currently unprofitable.

CLNN Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-9,292.5%
Free cash flow / Revenue

CLNN Quarterly Performance

Quarterly financial performance data for Clene Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $15.0K -$751.0K $-0.85
Q2 2025 $27.0K -$751.0K $-0.78
Q1 2025 $73.0K -$751.0K $-0.09
Q3 2024 $87.0K -$2.4M $-0.38
Q2 2024 $91.0K -$6.8M $-1.06
Q1 2024 $73.0K -$11.1M $-0.09
Q3 2023 $108.0K -$2.4M $-0.02
Q2 2023 $35.0K -$4.5M $-0.07

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

CLNN Capital Allocation

Operating Cash Flow
-$18.5M
Cash generated from operations
Capital Expenditures
$39.0K
Investment in assets
Dividends
None
No dividend program

CLNN SEC Filings

Access official SEC EDGAR filings for Clene Inc. (CIK: 0001822791)

📋 Recent SEC Filings

Date Form Document Action
Mar 17, 2026 10-K clnn20251231_10k.htm View →
Mar 17, 2026 8-K clnn20260316_8k.htm View →
Mar 12, 2026 8-K clnn20251022_8k.htm View →
Feb 24, 2026 8-K clnn20260223_8k.htm View →
Feb 20, 2026 4 xslF345X05/rdgdoc.xml View →

Frequently Asked Questions about CLNN

What is the AI rating for CLNN?

Clene Inc. (CLNN) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CLNN's key strengths?

Maintains modest cash position of $5.2M providing short-term runway. Revenue generation demonstrates some commercial traction despite minimal scale.

What are the risks of investing in CLNN?

Negative stockholders' equity of -$17.6M indicates technical insolvency and shareholder value destruction. Operating cash burn of -$18.5M annually with only $5.2M cash on hand creates critical liquidity crisis.

What is CLNN's revenue and growth?

Clene Inc. reported revenue of $200.0K.

Does CLNN pay dividends?

Clene Inc. does not currently pay dividends.

Where can I find CLNN SEC filings?

Official SEC filings for Clene Inc. (CIK: 0001822791) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CLNN's EPS?

Clene Inc. has a diluted EPS of $-0.46.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 22, 2026 | Data as of: 2025-12-31 | Powered by Claude AI